Home > Boards > US Listed > Biotechs > BELLUS Health Inc. (BLUSF)

The Phase III Confirmatory Study is designed to

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
SmurfVA Member Profile
 
Followed By 64
Posts 6,721
Boards Moderated 2
Alias Born 02/07/13
160x600 placeholder
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 9/25/2019 6:01:06 AM
Statement of Beneficial Ownership (sc 13d) Edgar (US Regulatory) - 9/18/2019 4:17:39 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/17/2019 4:16:11 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/17/2019 11:05:41 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 9/16/2019 10:53:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/9/2019 9:28:32 AM
Voluntary Supplemental Material Filed Pursuant to Section 11(a) of the Securities Act of 1933 by Foreign Issuers (suppl) Edgar (US Regulatory) - 9/5/2019 3:53:52 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/5/2019 7:39:28 AM
Certification by the Exchange Approving Securities for Listing (cert) Edgar (US Regulatory) - 9/4/2019 5:01:51 PM
Amended Registration Statement for Securities of Certain Canadian Issuers Under the Securities Act of 1933 (f-10/a) Edgar (US Regulatory) - 9/4/2019 4:45:14 PM
Securities Registration (section 12(b)) (8-a12b) Edgar (US Regulatory) - 9/3/2019 8:18:20 AM
Appointment of Agent for Service of Process and Undertaking (f-x) Edgar (US Regulatory) - 9/3/2019 8:10:18 AM
Registration Statement for Securities of Certain Canadian Issuers Under the Securities Act of 1933 (f-10) Edgar (US Regulatory) - 9/3/2019 7:54:49 AM
Amended Small Company Offering and Sale of Securities Without Registration (d/a) Edgar (US Regulatory) - 1/29/2019 10:29:52 AM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 1/11/2019 11:25:48 AM
SmurfVA   Thursday, 01/30/14 12:57:18 AM
Re: fam401 post# 240
Post # of 261 
The Phase III Confirmatory Study is designed to confirm the safety and efficacy of KIACTATM, previously demonstrated in a Phase II/III study, in preventing kidney function decline in patients diagnosed with AA amyloidosis. AA amyloidosis is an orphan indication resulting in kidney dysfunction that often rapidly leads to dialysis and death.

The study is expected to enroll approximately 230 patients from more than 70 sites in 30 countries worldwide. To date, the study has enrolled approximately 200 patients. Enrollment is expected to be completed in the second quarter of 2014.

Product pipelines. ref. http://www.bellushealth.com/English/products/product-pipeline-overview/default.aspx


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist